Diffuse Large B-cell Lymphoma

Mogamulizumab Offers Glimmer of Hope for Relapsed T-cell Lymphomas

Clinical Trial: Epcoritamab to Be Evaluated in R/R DLBCL

By

Rachel Narozniak, MA

March 9, 2021

Investigators of a phase 3 trial will compare epcoritamab with investigator’s choice of chemotherapy in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.

Risk Factors for Early Relapse of DLBCL After CAR-T Therapy

By

Andrea S. Blevins Primeau, PhD, MBA

November 30, 2020

Nearly half of all relapses occurred within the first month of CAR-T infusion.

Loncastuximab Tesirine Gets Priority Review for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

By

Brian Park, PharmD

November 25, 2020

Loncastuximab tesirine is an antibody drug conjugate composed of a humanized monoclonal antibody directed against human CD19 and conjugated through a linker to a pyrrolobenzodiazepine dimer cytotoxin.

Novel immunotherapies and small molecule pathway inhibitors are transforming the standard of care for some of the most challenging lymphoma subtypes.

Cardiovascular Risk With Doxorubicin Highlights Need for Early Surveillance

By

Christina Bennett, MS

October 30, 2020

Exposure to doxorubicin during treatment for DLBCL was linked to a higher risk for cardiovascular diseases, highlighting the need for early cardiac surveillance.

A pregnant woman speaks with her doctor

Pregnant Patients With Non-Hodgkin Lymphoma May Receive Chemotherapy

By

Patricia Chaney

October 15, 2020

Pregnant patients with non-Hodgkin lymphoma may be able to receive CHOP-like chemotherapy during pregnancy with some risks.

The signaling pathways detected may shed light on new treatment strategies.

New Analysis of the Tumor Microenvironment Reveals 3 Subtypes in Large B-Cell Lymphoma of the Brain

By

Monique Brouillette

October 1, 2020

The signaling pathways detected may shed light on new treatment strategies.

Consolidative radiotherapy use after multi-agent chemotherapy for treatment of diffuse large B-cell

Lisocabtagene Maraleucel for Relapsed/Refractory Large B-Cell Lymphomas

By

Vicki Moore, PhD

September 29, 2020

Investigators assessed safety and efficacy outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.

2021 Update on Diagnosis, Risk Stratification, and Management of Cutaneous B-Cell Lymphomas

By

Rita Aghjayan

September 8, 2020

Researchers assessed diagnosis, risk-stratification, and management of 3 distinct subgroups of primary cutaneous lymphomas.

Lipid Microenvironment With B-Cell Lymphoma and Natural Killer Cell Function

By

Vicki Moore, PhD

September 3, 2020

Lipid changes in the B-cell lymphoma microenvironment may influence natural killer cell metabolism and function.

Computer artwork of HIV in the bloodstream.

Survival Outcomes and HIV Status Among Patients With Plasmablastic Lymphoma

By

Jonathan Goodman, MPhil

August 24, 2020

Researchers studied clinical characteristics linked to overall survival and lymphoma-specific survival in patients with plasmablastic lymphoma.

Next post in Lymphoma

A recent article is only the latest in a series of studies drawing attention to the importance of di

Improving Survival in Younger Patients With Waldenström Macroglobulinemia